

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/789,400-Conf. #5376
				Filing Date	February 27, 2004
				First Named Inventor	Stephane BIACCHESI
				Art Unit	1632
				Examiner Name	S. L. Chen
Sheet	1	of	2	Attorney Docket Number	1173-1061PUS3

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)			
	BA	WO-03/072719	09-04-2003	Medimmune Vaccines Inc et al.	
	BB	WO-2004/027037-A	04-01-2004	Nasa et al.	
	BC	WO-05/014626	02-17-2005	Us Health et al.	
	BD	WO-04/05881	01-15-2004	Biovitrum Ab et al.	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/789,400-Conf. #5376
				Filing Date	February 27, 2004
				First Named Inventor	Stephane BIACCHESI
				Art Unit	1632
				Examiner Name	S. L. Chen
Sheet	2	of	2	Attorney Docket Number	1173-1061PUS3

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	Tang, R.S., et al., "Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3' Proximal Genome Positions of Bovine/Human Parainfluenza virus Type 3 on Virus Replication and Immunogenicity," J.Viro., Vol 77, No 20, pp 10819-10828 (2003)		
	CB	Biacchesi, S., et al., "Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes," J.Viro., Vol 321, No 2, pp 247-259 (2004).		
	CC	Skiadopoulos, M.H., et al., "The Two Major Human Metapneumovirus Genetic Lineages Are Highly Related Antigenically, and the Fusion (F) Protein Is a Major Contributor to This Antigenic Relatedness," J.Viro., Vol 78, No 13, pp 6927-6937 (2004).		
	CD	Herfst, S., "Recovery of Human Metapneumovirus Genetic Lineages A and B from Cloned cDNA," J.Viro., Vol 78, No 15, pp 8264-8270 (2004).		
	CE	Biacchesi, S., et al., "Genetic diversity between human metapneumovirus subgroups," Virology, Vol 315, No 1, pp 1-9 (2003).		
	CF	van den Hoogen, B.G., et al., "Analysis of the Genomic Sequence of a Human Metapneumovirus," Virology, Vol 295, No 1, pp 119-132 (2002).		
	CG	Collins, P.L., et al., "Respiratory Syncytial Virus: Reverse Genetics and Vaccine Strategies," Virology, Vol 296, No 2, pp 204-211 (2002).		
	CH	Crowe, James E., Jr., "Respiratory syncytial virus vaccine development," Vaccine, Vol 20, pp S32-S37 (2001).		
	CI	Biacchesi, S., et al., "Recombinant Human Metapneumovirus Lacking the Small Hydophobic SH and/or Attachment G Glycoprotein: Deletion of G Yields a Promising Vaccine Candidate," J.Viro., Vol 78, No 23, pp 12877-12887 (2004).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.